| Name | Title | Contact Details |
|---|
Cherokee Nation Health Services is the largest tribally-operated health system in the country and offers a variety of services to Cherokee Nation citizens, as well as citizens of other federally recognized tribes. Through the health system, the tribe operates eight health centers and W.W. Hastings Hospital within the tribe`s 14-county jurisdiction. On the Hastings campus a 469,000 square foot outpatient health facility will also open this fall.
NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company`s Nature`s Bounty® (www.NaturesBounty.com), Vitamin World® (www.VitaminWorld.com), Puritan`s Pride® (www.Puritan.com), Holland and Barrett® (www.HollandAndBarrett.com), Rexall® (www.Rexall.com), Sundown® (www.Sundownnutrition.com), MET-Rx® (www.MetRX.com), WORLDWIDE Sport Nutrition® (www.SportNutrition.com), American Health® (www.AmericanHealthUS.com), GNC (UK)® (www.GNC.co.uk), DeTuinen® (www.DeTuinen.nl), LeNaturiste (www.LeNaturiste.com), SISU® (www.SISU.com), Solgar® (www.Solgar.com) and Ester-C® (www.Ester-C.com) brands.
Blue Ridge HealthCare Systems is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Blue Ridge HealthCare Systems is based in Morganton, NC. You can find more information on Blue Ridge HealthCare Systems at www.blueridgehealth.org
Havas Health houses Havas Life (formerly known as Euro RSCG Life), Health4brands (H4B), and Havas Lynx, three wholly-owned Health and Communications Networks, and defines policies and processes for the entire group. Its customer-centric approach has the talent, tenacity and technology that companies, brands and people need to thrive in today`s world.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.